CoChat
Sign Up
Cited by 255Chronic Kidney Disease and DiabetesLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)

Colhoun, Helen M., Betteridge, D. John, Durrington, Paul N., Hitman, Graham A., Neil, H. Andrew W., Livingstone, Shona J., Charlton-Menys, Valentine, DeMicco, David A., Fuller, John H.·2009·American Journal of Kidney Diseases
DOI 10.1053/j.ajkd.2009.03.022
Open this paper in CoChat — free account

Abstract

Background We examined whether atorvastatin affects diabetic kidney disease and whether the effect of atorvastatin on cardiovascular disease (CVD) varies by kidney status in patients with diabetes. Study design The Collaborative Atorvastatin Diabetes Study (CARDS) randomized placebo-controlled trial. Setting & participants Patients with type 2 diabetes and no prior CVD (n = 2,838). Intervention Random allocation to atorvastatin, 10 mg/d, or placebo, with a median follow-up of 3.9 years. Outcomes Estimated glomerular filtration rate (eGFR), albuminuria, CVD. Measurements Baseline and follow-up GFRs were estimated by using the Modification of Diet in Renal Disease Study equation. Urinary albumin-creatinine ratio was measured on spot urine samples. Results At baseline, 34% of patients had an eGFR of 30 to 60 mL/min/1.73 m(2). Atorvastatin treatment was associated with a modest improvement in annual change in eGFR (net, 0.18 mL/min/1.73 m(2)/y; 95% confidence interval [CI], 0.04 to 0.32; P = 0.01) that was most apparent in those with albuminuria (net improvement, 0.38 mL/min/1.73 m(2)/y; P = 0.03). At baseline, 21.5% of patients had albuminuria and an additional 6.8% developed albuminuria during follow-up. Atorvastatin did not influence the incidence of albuminuria (hazard ratio, 1.49; 95% CI, 0.73 to 3.04; P = 0.3) or regression to normoalbuminuria (hazard ratio, 1.19; 95% CI, 0.57 to 2.49; P = 0.6). In 970 patients with a moderately decreased eGFR of 30 to 60 mL/min/1.73 m(2),…

Overview

Integrity signals

Registry

Crossref · 10.1053/j.ajkd.2009.03.022

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 25 references

Cited by

Sorted by citations

Items 101–200 of 255

Related

See all

Metadata

Authors
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., & Fuller, J. H.
Affiliations
  • University of Dundee (GB)
  • University College Hospital (GB)
  • University of Manchester (GB)
  • Queen Mary University of London (GB)
  • University of Oxford (GB)
  • Pfizer (United States) (US)
  • The Royal Free Hospital (GB)
Corresponding author
Colhoun, Helen M.
ORCID
Venue
American Journal of Kidney Diseases
Publisher
Elsevier BV
Published
2009-11
Volume
54
Issue
5
Pages
810-819
ISSN
0272-6386 (ISSN-L)
DOI
10.1053/j.ajkd.2009.03.022
OpenAlex
W2029977823
Cited by
255
References
25
Citations by year
2026: 3 · 2025: 3 · 2024: 10 · 2023: 7 · 2022: 8 · 2021: 15 · 2020: 13 · 2019: 10 · 2018: 10 · 2017: 11 · 2016: 18 · 2015: 19 · 2014: 44 · 2013: 20 · 2012: 32
FWCI
14.59
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • American Journal of Kidney Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Funders
  • National Institute for Health and Care Research
  • NIH Clinical Center
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
atorvastatin, type 2 diabetes, diabetic nephropathy, albuminuria, estimated glomerular filtration rate, cardiovascular disease, stroke, statins, albumin-creatinine ratio, cardioprotection, estimated glomerular filtration rate decline
MeSH terms
Atorvastatin, Aged, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Female, Glomerular Filtration Rate, Heptanoic Acids, Humans, Male, Middle Aged, Pyrroles, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review